Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

• Status: Completed
• Trial end date: 2018-12-15
• Target enrollment: 0
• Participant gender: All

Summary

This is a study aiming to investigate a possible correlation between the parameters affecting the physicians' therapeutic choice with the patients' overall adherence to osteoporosis treatment. Secondary end-points include correlation between the parameters affecting the physicians' therapeutic choice and the patients' quality of life as well as the evaluation of the whole osteoporosis treatment approach of orthopedic surgeons in Greece (diagnostic means, use of diagnostic and treatment guidelines, methodology of follow - up).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: 251 Hellenic Air Force & VA General Hospital
• Collaborator: Hellenic Osteoporosis Foundation (www.http://heliost.gr/en/)
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Female patients with postmenopausal osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study.

• Male patients ≥ 50 years old with idiopathic osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study.

• Male and female patients with steroid-induced osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study.

Exclusion Criteria:

• Prior use of teriparatide or PTH(1-84)

• Hypersensitivity to teriparatide regimen.

• Pregnancy and lactation.

• Hypercalcamia.

• Renal deficiency (eGFR < 30 ml/min).

• Other bone metabolic diseases (including hyperparathyroidism and Paget's disease) except primary osteoporosis or steroid induced osteoporosis .

• Uninterpretable increases of alkaline phosphatase (ALP)

• Prior skeletal radiotherapy.

• Skeletal malignancies or bone metastases